Table of Contents
INDIANAPOLIS — LDI Ltd. has acquired UltiMed Inc., a manufacturer of injection-related devices for the consumer, institutional and veterinary markets.
Terms of the acquisition agreement weren’t disclosed. UltiMed’s drug injection delivery devices include insulin syringes, pen needles and safety syringes for the domestic and international markets. The Minneapolis-based company owns and operates manufacturing facilities in De Smet, S.D., and Gong-Ju, South Korea.
LDI noted that UltiMed provides diabetes patients with smooth, comfortable injection devices, and its products are used by pharmacies, physician offices, health care facilities and veterinary clinics.
In particular, LDI said UltiMed’s UltiGuard packaging system makes the company a leader in safe needle disposal. UltiGuard combines convenient needle storage and a sharps disposal container in one system, ensuring that used needles are properly contained after use.
"Our manufacturing business is a great fit with LDI," commented Jim Erikson, UltiMed’s president. "We welcome LDI’s experience in distribution and their culture as a family office. We are excited to partner together to grow our business."
UltiMed markets its products under the UltiCare brand, as well as under private-label and co-branding arrangements, according to LDI.
"Finding the next platform business has been a top priority for LDI," stated J.A. Lacy, president and chief executive officer of LDI. "Jim Erickson and the UltiMed management team have built a growing and profitable company based on high-quality, user-friendly products and a commitment to customer service. We are excited to work with the UltiMed team on a strategy to accelerate their growth and welcome them to the LDI family."
